HomeCompareDM vs ABBV

DM vs ABBV: Dividend Comparison 2026

DM yields 40.32% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.3K in total portfolio value· pulled ahead in Year 4
10 years
DM
DM
● Live price
40.32%
Share price
$4.96
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.4K
Annual income
$5.49
Full DM calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — DM vs ABBV

📍 ABBV pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DM + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DM pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DM
Annual income on $10K today (after 15% tax)
$3,427.42/yr
After 10yr DRIP, annual income (after tax)
$4.67/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,862.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DM + ABBV for your $10,000?

DM: 50%ABBV: 50%
100% ABBV50/50100% DM
Portfolio after 10yr
$66.1K
Annual income
$12,865.61/yr
Blended yield
19.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DM
Analyst Ratings
3
Buy
6
Hold
1
Sell
Consensus: Hold
Price Target
$5.25
+5.8% upside vs current
Range: $5.00 — $5.50
Altman Z
-12.2
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DM buys
0
ABBV buys
0
No recent congressional trades found for DM or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMABBV
Forward yield40.32%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$27.4K$104.7K
Annual income after 10y$5.49$25,725.73
Total dividends collected$4.5K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$5.25$256.15

Year-by-year: DM vs ABBV ($10,000, DRIP)

YearDM PortfolioDM Income/yrABBV PortfolioABBV Income/yrGap
1$12,716$2,016.13$11,559$438.51+$1.2KDM
2$14,804$1,198.01$13,494$640.86+$1.3KDM
3$16,492$651.74$15,951$945.97+$541.00DM
4← crossover$17,986$339.28$19,152$1,413.89$1.2KABBV
5$19,418$172.90$23,443$2,146.38$4.0KABBV
6$20,864$87.23$29,391$3,321.96$8.5KABBV
7$22,369$43.80$37,948$5,265.87$15.6KABBV
8$23,957$21.94$50,795$8,596.74$26.8KABBV
9$25,644$10.98$71,034$14,549.41$45.4KABBV
10$27,445$5.49$104,715$25,725.73$77.3KABBV

DM vs ABBV: Complete Analysis 2026

DMStock

Desktop Metal, Inc. engages in manufacture and sale of additive manufacturing technologies for engineers, designers, and manufacturers in the Americas, Europe, the Middle East, Africa, and the Asia- Pacific. The company offers Production System, an industrial manufacturing solution; Shop System, a mid-volume binder jetting platform; X-series platform for serial production binder jet 3D printed metal, ceramic, or composite parts, balancing speed, and quality; and Studio System, an office metal 3D printing system; and Fiber platform that offers a desktop 3D printer. In addition, it provides Xtreme 8K platform, designed for industrial, high-temperature production of end-use photopolymer parts, and uses high-powered light sources with a water-cooled DLP chip; Einstein series, designed for dental professionals which offers 3D printing; P4K platform offers series of advanced DLP printer models designed for volume production in precision applications; Envision One platform; which leverages patented CDLM technology for high-volume production of end-use photopolymer parts; D4K Pro platform, designed for jewelry and chairside settings; S-Max platform, which provides digital casting solution; and Robotic Additive Manufacturing, or RAM, platform that offers robotic 3D printing solutions. Further, the company offers S-Print, an entry-level solution for prototypes and small series production in digital casting applications; and 3D-Bioplotter platform which offers biofabrication solution. Additionally, the company provides binder jetting materials, DLP and CDLM photopolymer resins, BMD materials, micro-AFP materials, and bioprinting materials. It serves automotive, aerospace, healthcare and dental, consumer products, heavy industry, machine design, and research and development industries. The company was founded in 2015 and is headquartered in Burlington, Massachusetts.

Full DM Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DM vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DM vs SCHDDM vs JEPIDM vs ODM vs KODM vs MAINDM vs JNJDM vs MRKDM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.